Phase 1 study of trebananib (AMG 386), an angiogenesis targeting angiopoietin-1/2 antagonist, in Japanese patients with advanced solid tumors

PURPOSE: To evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of trebananib (AMG 386)—a first-in-class angiopoietin-1/2 antagonist peptide-Fc fusion protein—in Japanese patients, we conducted a phase 1, dose escalation study. METHODS: Eligible patients were men or women, ag...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Doi, Toshihiko, Ohtsu, Atsushi, Fuse, Nozomu, Yoshino, Takayuki, Tahara, Makoto, Shibayama, Kazuhiro, Takubo, Takatoshi, Weinreich, David M.
Materialtyp: Artigo
Språk:Inglês
Publicerad: Springer-Verlag 2012
Ämnen:
Original Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC3535401/
https://ncbi.nlm.nih.gov/pubmed/23124648
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-012-2000-1
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk